Compared to controls, Zfx-siRNA treated cells showed decreased proliferation, increased AMN-107 solubility dmso apoptosis, and an increase in the proportion of cells in S and subG1 phases. Thus, Zfx promotes U251 cell growth. Our data suggest that Zfx may be related to cell cycle checkpoints in U251 cells. The cell has developed a series of checkpoints to ensure quality control over

proliferation. In particular, S phase represents a critical period for cells to commit to proliferation or undergo growth arrest [17]. Understanding the regulation of the S phase transition is central to the study of many diseases, particularly Aurora Kinase inhibitor cancer [18, 19]. The cell cycle is a well regulated process that depends on the combined action of both cell cycle activators and inhibitors [20]. With the emergence of the cancer stem cell theory, many researchers now believe that glioma stem cells are at the root of disease recurrence due in large part to their natural drug resistance and insensitivity to radiation therapy, Thus, successful tumor treatment likely depends on complete eradication of tumor stem cells [21]. Cancer stem cells with self-renewal capability can constitute a tumor by proliferation and differentiation, key processes in the formation, proliferation,

and invasiveness of cancer [22, 23]. Zfx may be a key gene involved in the molecular basis of stem cells, and this also potentially implicates it in cancer stem cell biology. However, whether Zfx plays a role in glioma stem cell self-renewal growth is currently unknown. In summary, our study highlights critical Selleckchem ICG-001 roles for Zfx in the human malignant glioma cell line U251. This study may provide the basis for further exploration of the role of Zfx in the occurrence and development of human glioma. We will continue to work on the mechanism by which Zfx influences glioma cell biology. Acknowledgement We thank Genechem for providing us with the lentiviral particles and technical assistance. This work was partially supported by major issues Foundation of health department in Jiangsu province

(K201106) and Suzhou science and technology plan projects (SYS201025). References 1. Surawicz TS, McCarthy BJ, Kupelian Teicoplanin V, Jukich PJ, Bruner JM, Davis FG: Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999, 1:14–25.PubMed 2. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 2000, 27:1–10.PubMed 3. Wechsler-Reya R, Scott MP: The developmental biology of brain tumors. Annu Rev Neurosci 2001, 24:385–428.PubMedCrossRef 4. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci USA 2000, 97:6242–6244.PubMedCrossRef 5. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.